VR Adviser
Latest statistics and disclosures from VR Adviser's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APGE, MTSR, OCUL, CDTX, VRDN, and represent 48.52% of VR Adviser's stock portfolio.
- Added to shares of these 8 stocks: MAZE (+$32M), CDTX (+$30M), Vor Biopharma (+$24M), SVRA (+$14M), CTMX (+$5.1M), OCUL, TENX, SEPN.
- Started 2 new stock positions in MAZE, Vor Biopharma.
- Reduced shares in these 6 stocks: ABVX (-$65M), PHVS (-$34M), UPB (-$21M), ELVN (-$16M), COGT (-$11M), DNTH.
- VR Adviser was a net seller of stock by $-37M.
- VR Adviser has $1.8B in assets under management (AUM), dropping by 33.14%.
- Central Index Key (CIK): 0001615982
Tip: Access up to 7 years of quarterly data
Positions held by VR Adviser consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for VR Adviser
VR Adviser holds 33 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apogee Therapeutics (APGE) | 19.0 | $337M | 8.5M | 39.73 |
|
|
| Mestera (MTSR) | 11.0 | $196M | 3.8M | 52.33 |
|
|
| Ocular Therapeutix (OCUL) | 8.7 | $154M | +3% | 13M | 11.69 |
|
| Cidara Therapeutics Com New (CDTX) | 5.1 | $91M | +48% | 947k | 95.76 |
|
| Miragen Therapeutics (VRDN) | 4.7 | $84M | 3.9M | 21.58 |
|
|
| Kalvista Pharmaceuticals (KALV) | 4.6 | $82M | 6.7M | 12.18 |
|
|
| Oruka Therapeutics (ORKA) | 4.5 | $80M | 4.1M | 19.23 |
|
|
| Oric Pharmaceuticals (ORIC) | 4.5 | $79M | 6.6M | 12.00 |
|
|
| Enliven Therapeutics (ELVN) | 3.7 | $66M | -19% | 3.2M | 20.47 |
|
| Cogent Biosciences (COGT) | 3.2 | $57M | -15% | 4.0M | 14.36 |
|
| Cytomx Therapeutics (CTMX) | 2.8 | $50M | +11% | 16M | 3.19 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.8 | $49M | -57% | 577k | 84.90 |
|
| Savara (SVRA) | 2.5 | $45M | +42% | 13M | 3.57 |
|
| Spyre Therapeutics Com New (SYRE) | 2.5 | $45M | 2.7M | 16.76 |
|
|
| Erasca (ERAS) | 2.2 | $39M | 18M | 2.18 |
|
|
| Dianthus Therapeutics (DNTH) | 2.1 | $38M | -3% | 961k | 39.35 |
|
| Engene Holdings (ENGN) | 1.9 | $35M | 5.0M | 6.83 |
|
|
| Maze Therapeatics (MAZE) | 1.8 | $32M | NEW | 1.2M | 25.93 |
|
| Jade Biosciences Com New (JBIO) | 1.6 | $28M | 3.2M | 8.63 |
|
|
| Dyne Therapeutics (DYN) | 1.5 | $28M | 2.2M | 12.65 |
|
|
| Vor Biopharma Com New | 1.4 | $24M | NEW | 500k | 48.72 |
|
| Upstream Bio (UPB) | 1.2 | $22M | -49% | 1.2M | 18.81 |
|
| Zura Bio Class A Ord Shs (ZURA) | 1.1 | $20M | 4.6M | 4.33 |
|
|
| Astria Therapeutics (ATXS) | 1.0 | $18M | 2.5M | 7.28 |
|
|
| Pharvaris N V (PHVS) | 0.9 | $17M | -67% | 675k | 24.95 |
|
| Crescent Biopharma (CBIO) | 0.9 | $17M | 1.4M | 11.89 |
|
|
| Septerna (SEPN) | 0.6 | $12M | +13% | 611k | 18.81 |
|
| Cullinan Oncology (CGEM) | 0.5 | $8.2M | 1.4M | 5.93 |
|
|
| Surrozen Com New (SRZN) | 0.5 | $8.2M | 633k | 12.88 |
|
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.4 | $8.0M | 750k | 10.60 |
|
|
| Artiva Biotherapeutics (ARTV) | 0.3 | $4.6M | 1.6M | 2.87 |
|
|
| Tenax Therapeutics Com New (TENX) | 0.2 | $3.3M | +344% | 438k | 7.61 |
|
| Casi Pharmaceuticals Ord Shs (CASI) | 0.1 | $1.6M | 987k | 1.66 |
|
Past Filings by VR Adviser
SEC 13F filings are viewable for VR Adviser going back to 2020
- VR Adviser 2025 Q3 filed Nov. 14, 2025
- VR Adviser 2025 Q2 filed Aug. 14, 2025
- VR Adviser 2025 Q1 filed May 15, 2025
- VR Adviser 2024 Q4 filed Feb. 14, 2025
- VR Adviser 2024 Q3 filed Nov. 14, 2024
- VR Adviser 2024 Q2 filed Aug. 14, 2024
- VR Adviser 2024 Q1 filed May 15, 2024
- VR Adviser 2023 Q4 filed Feb. 14, 2024
- VR Adviser 2023 Q3 filed Nov. 14, 2023
- VR Adviser 2023 Q2 filed Aug. 11, 2023
- VR Adviser 2022 Q2 restated filed May 15, 2023
- VR Adviser 2022 Q3 restated filed May 15, 2023
- VR Adviser 2022 Q4 restated filed May 15, 2023
- VR Adviser 2023 Q1 filed May 15, 2023
- VR Adviser 2022 Q4 filed Feb. 14, 2023
- VR Adviser 2022 Q3 filed Nov. 14, 2022